➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Johnson and Johnson
McKesson
Moodys
McKinsey

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PONATINIB HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Ponatinib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00660920 ↗ Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Active, not recruiting Ariad Pharmaceuticals Phase 1 2008-05-01 The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule (QD) in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
NCT01207440 ↗ Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Active, not recruiting Ariad Pharmaceuticals Phase 2 2010-09-01 The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation.
NCT01424982 ↗ Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting Ariad Pharmaceuticals Phase 2 2011-10-01 The goal of this clinical research study is to learn if intensive chemotherapy combined with ponatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied. Ponatinib may cause a blood clot to form in an artery or in a vein. Depending on the location of the clot, this could cause a heart attack, a stroke, severe damage to other tissue, or death. A blood clot may occur within 2 weeks after you start taking the drug. About 25% (1 in 4) of patients taking the drug form an abnormal clot. Blood clots can occur in patients that do not have other known risk factors for forming clots. If you develop a blood clot, you will need to stop taking ponatinib. In some cases, emergency surgery could be needed to remove the clot and restore blood flow.
NCT01424982 ↗ Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting M.D. Anderson Cancer Center Phase 2 2011-10-01 The goal of this clinical research study is to learn if intensive chemotherapy combined with ponatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied. Ponatinib may cause a blood clot to form in an artery or in a vein. Depending on the location of the clot, this could cause a heart attack, a stroke, severe damage to other tissue, or death. A blood clot may occur within 2 weeks after you start taking the drug. About 25% (1 in 4) of patients taking the drug form an abnormal clot. Blood clots can occur in patients that do not have other known risk factors for forming clots. If you develop a blood clot, you will need to stop taking ponatinib. In some cases, emergency surgery could be needed to remove the clot and restore blood flow.
NCT01549548 ↗ Compassionate Use Ponatinib No longer available Ariad Pharmaceuticals N/A 1969-12-31 The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.
NCT01549548 ↗ Compassionate Use Ponatinib No longer available OHSU Knight Cancer Institute N/A 1969-12-31 The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ponatinib Hydrochloride

Condition Name

Condition Name for Ponatinib Hydrochloride
Intervention Trials
Chronic Myeloid Leukemia 8
Leukemia 7
Acute Lymphoblastic Leukemia 6
Acute Myeloid Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ponatinib Hydrochloride
Intervention Trials
Leukemia 41
Leukemia, Myeloid 28
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24
Precursor Cell Lymphoblastic Leukemia-Lymphoma 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ponatinib Hydrochloride

Trials by Country

Trials by Country for Ponatinib Hydrochloride
Location Trials
United States 128
Japan 14
China 13
France 13
Australia 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ponatinib Hydrochloride
Location Trials
Texas 15
Oregon 10
Michigan 8
Massachusetts 7
Maryland 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ponatinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ponatinib Hydrochloride
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 1
Phase 2 35
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ponatinib Hydrochloride
Clinical Trial Phase Trials
Recruiting 24
Not yet recruiting 21
Active, not recruiting 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ponatinib Hydrochloride

Sponsor Name

Sponsor Name for Ponatinib Hydrochloride
Sponsor Trials
Ariad Pharmaceuticals 16
M.D. Anderson Cancer Center 9
National Cancer Institute (NCI) 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ponatinib Hydrochloride
Sponsor Trials
Other 49
Industry 28
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Express Scripts
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.